Hearts & Minds Blog

Esperion Investor Day: Lighting the Way for Phase 2b Results

Tim Mayleben

President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day… more

Reflections One Year Post-IPO

Tim Mayleben

President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million… more

Posted In: Company News

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

Tim Mayleben

President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the… more

Posted In: Industry Insights

Providing an Alternative for LDL-C Lowering

Tim Mayleben

President and Chief Executive Officer

Brian Orelli’s recent article in BioWorld Insight, “Avoiding the PCSK9 frenzy with alternative drug targets,” highlights how the focus and… more

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

Tim Mayleben

President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since… more

Posted In: Company News